Kinase inhibitors (like BTK) are beneficial regulators of life-threatening symptoms of COVID-19, including anti-inflammatory, cytokine suppression and antifibrotic activity [27,28,29,30,31,32]. This evidence concerns the gene BTK and COVID-19.